BiomX Issues Statement Regarding Recent Common Stock Trading Activity

BiomX (NYSE American: PHGE) issued a statement on January 27, 2026 addressing recent unusual trading in its common stock.

Rhea-AI Summary

BiomX (NYSE American: PHGE) issued a statement on January 27, 2026 addressing recent unusual trading in its common stock. The company said it is not aware of any undisclosed material developments in its business or affairs that would explain the activity.

BiomX noted that NYSE American contacted the company per usual practice and requested this statement. The company indicated it does not intend to provide further comment about market speculation or trading activity.

Argus Jan 27 session

+69.51% close to close Open Argus

Details

News Market Reaction – PHGE

On Jan 27, the day this news came out, PHGE closed 69.51% above the previous close.

Data tracked by StockTitan Argus for the Jan 27 session.

Market Context

On Jan 27, the day this news came out, the stock closed 69.5% above the previous close. A strong pos...

Analysis

On Jan 27, the day this news came out, the stock closed 69.5% above the previous close. A strong positive reaction aligns with the stock’s history of moving in step with news tone, even when events are financial or structural. Recent catalysts included a 1-for-19 reverse split and a $3.0M private placement, plus earlier volatility around BX004. However, this statement explicitly cites no new undisclosed developments, so any large upside would have reflected trading dynamics and sector strength rather than fresh company fundamentals.

Historical Context

5 past events · Latest: Dec 29

5 events

1. Dec 29

   Private placement

   24h Move

   +3.6%

   Announced $3.0M private placement to support BX011 and strategic review.

2. Dec 08

   Trial discontinuation

   24h Move

   -36.9%

   Ended BX004 Phase 2b after high adverse events and began cost cuts.

3. Nov 25

   Clinical update

   24h Move

   +5.4%

   Provided BX004 Phase 2b safety update and pushed topline results to Q2 2026.

4. Nov 14

   Reverse stock split

   24h Move

   +7.5%

   Announced 1-for-19 reverse stock split and share count reduction.

5. Nov 12

   Earnings and update

   24h Move

   -1.9%

   Reported Q3 2025 results with limited cash and going concern language.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today issued a statement in response to recent unusual market activity in its common stock.

The Company is not aware of any material developments in its business or affairs that have not been previously disclosed, nor, to its knowledge, of any other reason that would account for the recent unusual market activity in its common stock.

NYSE American LLC has contacted the Company in accordance with its usual practice and has advised that the Company issue this statement. The Company does not intend to make any further comment on market speculation or trading activity.

About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.

Contacts:

BiomX, Inc.
Ben Cohen
Head Corporate Communications
benc@biomx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BiomX (PHGE) say about the January 27, 2026 unusual trading?

BiomX said it is not aware of any undisclosed material developments that would explain the recent unusual trading activity.

Did BiomX (PHGE) confirm any new business developments on January 27, 2026?

No. BiomX stated it is not aware of any material developments in its business or affairs that have not been previously disclosed.

Why did BiomX (PHGE) issue the trading statement on January 27, 2026?

The company said NYSE American contacted it in accordance with usual practice and advised that it issue a statement.

Will BiomX (PHGE) provide more details about the market activity after January 27, 2026?

BiomX stated it does not intend to make any further comment on market speculation or trading activity.

Does the January 27, 2026 statement from BiomX (PHGE) include financial or clinical updates?

No. The statement only addressed trading activity and said there were no undisclosed material developments; it did not provide financial or clinical updates.